0001209191-20-045581.txt : 20200806
0001209191-20-045581.hdr.sgml : 20200806
20200806191145
ACCESSION NUMBER: 0001209191-20-045581
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200806
FILED AS OF DATE: 20200806
DATE AS OF CHANGE: 20200806
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo Holdings A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 201083329
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
FORMER NAME:
FORMER CONFORMED NAME: Novo A/S
DATE OF NAME CHANGE: 20070130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001651431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364813934
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 978-503-2124
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-08-06
0
0001651431
Checkmate Pharmaceuticals, Inc.
CMPI
0001388325
Novo Holdings A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
SERIES C REDEEMABLE CONVERTIBLE PREFERRED STOCK
COMMON STOCK
1670100
D
The Series C Redeemable Convertible Preferred Stock is convertible into Common Stock on a 7.4771-for-1 basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. These shares have no expiration date.
Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
2020-08-06